| Name | Title | Contact Details |
|---|
Puget Sound Kidney Centers is a Everett, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target G protein coupled receptors, or GPCRs. We are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. We have identified four biased ligand drug candidates: TRV130, an FDA-designated Breakthrough Therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; TRV027 was evaluated in a Phase 2b study for the treatment of acute heart failure; TRV734 has completed phase 1 testing for oral treatment of acute and chronic pain; and TRV250 is in preclinical development for the treatment of migraine. In addition, Trevena has an early stage portfolio of drug discovery programs currently in lead optimization.
Drug Development Resources is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Strive Compounding Pharmacy, were pioneering a movement in personalized medicine. Ditching the one-size-fits-all approach, we specialize in customizing medications to fit the unique health conditions and wellness goals of each individual. Our commitment to whole-person health is evident in our comprehensive services ranging from hormone replacement and weight management to dermatology and veterinary care. As a rapidly growing company, we pride ourselves on our robust company culture, strong partnerships with healthcare providers, and the effectiveness, safety, and benefits of our compounded drugs. Our pursuit of uncompromised excellence in compounding, coupled with a proactive approach to healthcare, sets us apart in creating healthier and happier lives, while also educating the world on the crucial role that compound pharmacies play within a healthy society.
BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.